Palisade Bio, Inc.
Status: Publicly traded
Last reviewed: October 2026
Direct answer
Palisade Bio, Inc. is publicly traded on NASDAQ under the ticker PALI.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s...
Can you invest in Palisade Bio, Inc.?
Yes. Palisade Bio, Inc. trades publicly on NASDAQ as PALI.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Palisade Bio, Inc.
Detailed equity research is provided by MarketSnap.